NIGERIA · PHARMACEUTICALS
Key Facts
—The plant: The Sagamu facility carries a reported cost of about US$23 million and is described as the first full-scale antimalarial API plant in Africa. More than 90% of the civil works are complete and critical equipment is installed.
—What it has done already: The company’s in-house laboratory has synthesised five antimalarial APIs, among them artemether and lumefantrine. Antimalarials are the first product line, with HIV antiretrovirals and other essential medicines intended to follow.
—The delays: The facility was first targeted for 2024, then for late 2025, then for early 2026, and remains unfinished. No revised commissioning date was published with the bond.
